RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that it will release its fourth quarter and full year
2023 financial results after the market closes on Thursday, March 28, 2024, via press release,
which will be available on the Company's website
at https://ir.nrxpharma.com/press-releases. The Company will
host a conference call to discuss the financial results as well as
provide a corporate update at 4:30 p.m.
ET the same day.
A live webcast of the conference call will be available on the
Company's website at https://ir.nrxpharma.com/events. Participants
that are unable to join the webcast can access the conference call
via telephone by dialing domestically 1-877-704-4453, Int'l
Investors Dial 1-201-389-0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for HTX-100 (IV ketamine), through Hope Therapeutics,
in the treatment of suicidal depression, based on results of
well-controlled clinical trials conducted under the auspices of the
US National Institutes of Health and newly obtained data from
French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine
(NRX-100) by the US FDA as part of a protocol to treat patients
with acute suicidality.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-a-corporate-update-on-march-28-2024-302096432.html
SOURCE NRx Pharmaceuticals, Inc.